I agree Buckeyes and I can't imagine the technology isn't worth a lot more than it is trading for right now. That said it doesn't appear from the outside that the company is interested in getting any real business done. Paying huge fees ($ which they don't have) to get ready to sell an as yet unapproved drug seems foolish at best. If Eversana was only going to get paid upon success, as we were lead to believe, or if the company was well run and all cashed up I could see the Eversana strategy, but neither is the case here.  

Since the BoM conclusion all Don has done is "keep the lights on" at the cost of about 25% dilution. I don't have a problem with dilution but if it doesn't result in funding for forward progress, what is the point. If the company is not going to get a competent CEO at least do a licensing or partnering deal on one of the other compounds to keep the company looking alive and relevant. To support the share price, release all or part of the valuation that was performed by Deloitte(?) for Don's money mirage in the Middle East. He said the valuation supported a price well above the then current price of about $1 (correct me if I'm wrong). If Don was being truthful about that (I'm not saying he wasn't) he should prove it. Since that valuation the value of Apabetalone should have gone up given the covid and NAFLD potential. That valuation to me would at least provide a credible dollar figure to the technology. Don said at $.25 he knows a deal when he sees it.  Clearly the market needs a lot more than just the words of management that has pretty much zero credibility. 

Don should also be working on getting an investment by a big pharma. I find it hard to believe that if a big pharma was willing to fund a 5 year BoM that they wouldn't be interested in at least investing in the underlying technology.  For Resverlogix that would likely restore some credibility as well as signalling to the market that the company indeed has a future. It would also broaden the shareholder base. Trillium's stock benefited greatly when Pfizer made an above market investment in the company, before they bought the whole thing. 

Bottom line is that it is shameful to see such promising technology wasting away in the hands of management that has clearly demonstrated they don't know what they are doing.